Cargando…

Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses

Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhaohui, Fu, Lingyun, Xu, Yini, Hu, Xiaoxia, Yang, Hong, Zhang, Yanyan, Luo, Hong, Gan, Shiquan, Tao, Ling, Liang, Guiyou, Shen, Xiangchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156511/
https://www.ncbi.nlm.nih.gov/pubmed/32286474
http://dx.doi.org/10.1038/s41598-020-63498-3
_version_ 1783522223648145408
author Jiang, Zhaohui
Fu, Lingyun
Xu, Yini
Hu, Xiaoxia
Yang, Hong
Zhang, Yanyan
Luo, Hong
Gan, Shiquan
Tao, Ling
Liang, Guiyou
Shen, Xiangchun
author_facet Jiang, Zhaohui
Fu, Lingyun
Xu, Yini
Hu, Xiaoxia
Yang, Hong
Zhang, Yanyan
Luo, Hong
Gan, Shiquan
Tao, Ling
Liang, Guiyou
Shen, Xiangchun
author_sort Jiang, Zhaohui
collection PubMed
description Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effects of CVB-D on DCM remained unknown. The present aim was to explore the potential effects and underlying mechanisms of CVB-D on DCM. We explored the effects of CVB-D in DCM by using high fat high sucrose diet and streptozotocin-induced rat DCM model. Cardiac function and survival in rats with DCM were improved via the amelioration of oxidative damage after CVB-D treatment. Our data also demonstrated that pre-treatment with CVB-D exerted a remarkable cytoprotective effect against high glucose -or H(2)O(2) -induced neonatal rat cardiomyocyte damage via the suppression of reactive oxygen species accumulation and restoration of mitochondrial membrane potential; this effect was associated with promotion of Nrf2 nuclear translocation and its downstream antioxidative stress signals (NQO-1, Prdx1). Overall, the present data has provided the first evidence that CVB-D has potential therapeutic in DCM, mainly by activation of the Nrf2 signalling pathway to suppress oxidative stress. Our findings also have positive implications on the novel promising clinical applications of CVB-D.
format Online
Article
Text
id pubmed-7156511
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71565112020-04-19 Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses Jiang, Zhaohui Fu, Lingyun Xu, Yini Hu, Xiaoxia Yang, Hong Zhang, Yanyan Luo, Hong Gan, Shiquan Tao, Ling Liang, Guiyou Shen, Xiangchun Sci Rep Article Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effects of CVB-D on DCM remained unknown. The present aim was to explore the potential effects and underlying mechanisms of CVB-D on DCM. We explored the effects of CVB-D in DCM by using high fat high sucrose diet and streptozotocin-induced rat DCM model. Cardiac function and survival in rats with DCM were improved via the amelioration of oxidative damage after CVB-D treatment. Our data also demonstrated that pre-treatment with CVB-D exerted a remarkable cytoprotective effect against high glucose -or H(2)O(2) -induced neonatal rat cardiomyocyte damage via the suppression of reactive oxygen species accumulation and restoration of mitochondrial membrane potential; this effect was associated with promotion of Nrf2 nuclear translocation and its downstream antioxidative stress signals (NQO-1, Prdx1). Overall, the present data has provided the first evidence that CVB-D has potential therapeutic in DCM, mainly by activation of the Nrf2 signalling pathway to suppress oxidative stress. Our findings also have positive implications on the novel promising clinical applications of CVB-D. Nature Publishing Group UK 2020-04-14 /pmc/articles/PMC7156511/ /pubmed/32286474 http://dx.doi.org/10.1038/s41598-020-63498-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Jiang, Zhaohui
Fu, Lingyun
Xu, Yini
Hu, Xiaoxia
Yang, Hong
Zhang, Yanyan
Luo, Hong
Gan, Shiquan
Tao, Ling
Liang, Guiyou
Shen, Xiangchun
Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title_full Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title_fullStr Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title_full_unstemmed Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title_short Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses
title_sort cyclovirobuxine d protects against diabetic cardiomyopathy by activating nrf2-mediated antioxidant responses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156511/
https://www.ncbi.nlm.nih.gov/pubmed/32286474
http://dx.doi.org/10.1038/s41598-020-63498-3
work_keys_str_mv AT jiangzhaohui cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT fulingyun cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT xuyini cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT huxiaoxia cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT yanghong cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT zhangyanyan cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT luohong cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT ganshiquan cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT taoling cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT liangguiyou cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses
AT shenxiangchun cyclovirobuxinedprotectsagainstdiabeticcardiomyopathybyactivatingnrf2mediatedantioxidantresponses